Literature DB >> 32951096

Variations in native T1 values in patients with Duchenne muscular dystrophy with and without late gadolinium enhancement.

Sean M Lang1,2, Tarek Alsaied3,4, Philip R Khoury3,5, Thomas D Ryan3,4, Michael D Taylor3,4.   

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder leading to progressive skeletal and cardiac myopathy. Elevated myocardial T1 values correlate with fibrosis in most disease processes, but DMD skeletal and cardiac histopathology is defined by fibrofatty replacement that may result in a decrease in T1 values, due to the low T1 of fat. The study goal was to assess myocardial T1 values in DMD patients with and without late gadolinium enhancement (LGE). A retrospective analysis was performed on all patients with DMD referred for CMR at our institution from 7/5/2017 to 10/24/2018. T1 measurements were performed using breath-held modified Look Locker inversion recovery (MOLLI) sequences at the basal and mid-ventricular levels. The cohort was separated into patients without the presence of LGE (LGE-) and patients with current or previous LGE (LGE+). A total of 207 CMR studies were analyzed. The LGE- group comprised 88 patients while 119 patients were in the LGE+ group. The LGE+ group was older, had larger indexed LV end-diastolic volume and lower LV ejection fraction (LVEF) compared to the LGE- group. T1 values in the LGE+ group were lower compared to the LGE- group (mid T1 1012 ms vs. 1035 ms; p = 0.002), with 5 CMR studies demonstrating mid T1 values < 900 ms. There was no correlation between mid T1 and LVEF in the LGE- group. In the LGE+ cohort, lower T1 values correlated with worse LVEF (r = 0.34, p = 0.0002). The association between mid T1 values and LVEF remained statistically significant on multivariable analysis when accounting for number of LGE segments, LVEDVi, and age (p = 0.009). This is the largest study assessing native T1 values in patients with DMD. The results demonstrate that patients with LGE had lower T1 values than patients without LGE. In the LGE+ group, lower T1 values correlated with worse LV systolic function. These results are consistent with the evolving recognition of fibrofatty replacement in advanced stages of DMD myopathy. Furthermore, our study supports that there is not a simple linear relationship between increasing T1 values and advancing disease progression reported in most other cardiomyopathies.

Entities:  

Keywords:  Cardiac MR; Parametric mapping; Pediatric cardiomyopathies

Mesh:

Substances:

Year:  2020        PMID: 32951096     DOI: 10.1007/s10554-020-02031-z

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  44 in total

1.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

Authors:  Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

2.  107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

Authors:  K Bushby; F Muntoni; J P Bourke
Journal:  Neuromuscul Disord       Date:  2003-02       Impact factor: 4.296

3.  Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association.

Authors:  Brian Feingold; William T Mahle; Scott Auerbach; Paula Clemens; Andrea A Domenighetti; John L Jefferies; Daniel P Judge; Ashwin K Lal; Larry W Markham; W James Parks; Takeshi Tsuda; Paul J Wang; Shi-Joon Yoo
Journal:  Circulation       Date:  2017-08-24       Impact factor: 29.690

Review 4.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

5.  Evaluating Implementation of the Updated Care Considerations for Duchenne Muscular Dystrophy.

Authors:  Katherine S Ong; Kathi Kinnett; Rieza Soelaeman; Lauren Webb; Jennifer S Bain; Ann S Martin; Christina Westfield; Julie Bolen; Natalie Street
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

6.  Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry.

Authors:  David M Connuck; Lynn A Sleeper; Steven D Colan; Gerald F Cox; Jeffrey A Towbin; April M Lowe; James D Wilkinson; E John Orav; Leigha Cuniberti; Bonnie A Salbert; Steven E Lipshultz
Journal:  Am Heart J       Date:  2008-03-19       Impact factor: 4.749

7.  Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.

Authors:  Animesh Tandon; Chet R Villa; Kan N Hor; John L Jefferies; Zhiqian Gao; Jeffrey A Towbin; Brenda L Wong; Wojciech Mazur; Robert J Fleck; Joshua J Sticka; D Woodrow Benson; Michael D Taylor
Journal:  J Am Heart Assoc       Date:  2015-03-26       Impact factor: 5.501

8.  Echocardiographic Image Quality Deteriorates with Age in Children and Young Adults with Duchenne Muscular Dystrophy.

Authors:  Alyssa Power; Sabrina Poonja; Dal Disler; Kimberley Myers; David J Patton; Jean K Mah; Nowell M Fine; Steven C Greenway
Journal:  Front Cardiovasc Med       Date:  2017-12-20

Review 9.  Dystrophin and mutations: one gene, several proteins, multiple phenotypes.

Authors:  Francesco Muntoni; Silvia Torelli; Alessandra Ferlini
Journal:  Lancet Neurol       Date:  2003-12       Impact factor: 44.182

10.  Evaluation of Echocardiographic Measures of Left Ventricular Function in Patients with Duchenne Muscular Dystrophy: Assessment of Reproducibility and Comparison to Cardiac Magnetic Resonance Imaging.

Authors:  Jonathan H Soslow; Meng Xu; James C Slaughter; Michael Stanley; Kimberly Crum; Larry W Markham; David A Parra
Journal:  J Am Soc Echocardiogr       Date:  2016-08-17       Impact factor: 5.251

View more
  3 in total

Review 1.  Neuromuscular diseases and their cardiac manifestations under the spectrum of cardiovascular imaging.

Authors:  Georgios M Alexandridis; Efstathios D Pagourelias; Nikolaos Fragakis; Maria Kyriazi; Efthymia Vargiami; Dimitrios Zafeiriou; Vassilios P Vassilikos
Journal:  Heart Fail Rev       Date:  2022-07-20       Impact factor: 4.654

2.  Non-contrast cardiovascular magnetic resonance detection of myocardial fibrosis in Duchenne muscular dystrophy.

Authors:  Frank J Raucci; Meng Xu; Kristen George-Durrett; Kimberly Crum; James C Slaughter; David A Parra; Larry W Markham; Jonathan H Soslow
Journal:  J Cardiovasc Magn Reson       Date:  2021-04-29       Impact factor: 5.364

Review 3.  Role of CMR Imaging in Diagnostics and Evaluation of Cardiac Involvement in Muscle Dystrophies.

Authors:  Edyta Blaszczyk; Jan Gröschel; Jeanette Schulz-Menger
Journal:  Curr Heart Fail Rep       Date:  2021-07-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.